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Background: Women who undergo breast cancer surgery have a high risk of developing 
persistent pain. We investigated brain processing of painful stimuli using electroencephalo-
grams (EEG) to identify event-related potentials (ERPs) in patients with persistent pain after 
breast cancer treatment.
Methods: Nineteen patients (eight women with persistent pain, eleven without persistent 
pain), who were surgically treated more than 1 year previously for breast cancer (mastectomy, 
 lumpectomy, and axillary lymph node dissection) and/or had chemoradiotherapy, were recruited 
and compared with eleven healthy female volunteers. A block of 20 painful electrical stimuli was 
applied to the calf, somatopically remote from the initially injured or painful area. Simultaneously 
an EEG was recorded, and a visual analog scale (VAS) pain rating obtained.
Results: In comparison with healthy volunteers, breast cancer treatment without persistent 
pain is associated with accelerated stimulus processing (reduced P260 latency) and shows a 
tendency to be less intense (lower P260 amplitude). In comparison to patients without persistent 
pain, persistent pain after breast cancer treatment is associated with stimulus processing that 
is both delayed (ie, increased latency of the ERP positivity between 250–310 ms [P260]), and 
enhanced (ie, enhanced P260 amplitude).
Conclusion: These results show that treatment and persistent pain have opposite effects on 
cortical responsiveness.
Keywords: breast cancer surgery, persistent pain, nerve injury, event-related potentials, pain 
processing
Introduction
In recent years interest has grown in the alterations in brain processing present in 
patients with persistent pain. Brain imaging techniques such as functional magnetic 
resonance imaging (fMRI) and positron emission tomography (PET) have been used to 
investigate brain function by measuring the evoked response to applied somatosensory 
stimuli.1,2 The results regarding altered pain processing by the brain in the context of 
persistent pain are highly incongruent, perhaps due to large variability between the 
patients regarding pain history, pain etiology, pain distribution, and psychological 
characteristics.1,2
Use of a postoperative model may help overcome some of these problems, because 
it permits study of a homogenous patient population regarding pain etiology, pain 
distribution, and treatment. Furthermore, this model makes it possible to differentiate 
between the effect of treatment and the effect of pain because a comparative patient 
group (same treatment, but no pain) can be included for comparison.
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It has been shown that women who undergo surgery 
for breast cancer have a high risk of developing persistent 
postsurgical pain.3–6 This pain persistence is difficult to treat 
and is accompanied by a significantly diminished quality 
of life.5,7
The often used generic term “postmastectomy pain 
 syndrome” in cases of persistent pain after breast cancer treat-
ment might suggest a homogeneous disease category. But 
this is debatable.8 In fact, different types of pain have been 
observed after breast cancer treatment, like phantom breast 
pain,3,9 scar pain,10 neuropathic pain,6 complex regional pain 
syndrome,11 pain arising from the axillary web syndrome,12 
and the more recently prospectively investigated myofascial 
pain syndrome, which is typically observed during the first 
year after breast surgery including axillary lymph node 
 dissection (ALND).13
The etiology of persistent pain after breast cancer 
treatment is probably multifactorial.8 This is because 
breast cancer treatment includes different types of surgical 
interventions (eg, mastectomy, lumpectomy, sentinel 
lymph node biopsy, and ALND), and adjuvant therapies 
like chemotherapy, radiation and endocrine therapies. All 
these interventions may contribute to the development of 
persistent pain, and could have their own characteristics. 
However, nerve damage and radiotherapy appear to be 
significant risk factors.8
A frequently observed phenomenon in persistent post-
surgical pain conditions, and also in patients after breast 
cancer surgery, is a change in the sensitivity of tactile and 
pain processing. This change consists of a combination of 
sensory loss, particularly in the skin innervated by possibly 
damaged nerves, and hypersensitivity.4,6,8,14,15
To our knowledge, studies investigating the evoked brain 
response using electroencephalography (EEG) in the context 
of persistent postsurgical pain are scarce.2,16 In contrast to 
fMRI and PET, EEG directly measures neuronal activity; 
furthermore, it makes it possible to study the sequential 
activation of different brain structures in time. The aim of 
this study is to investigate brain processing of painful stimuli 
using EEG (or more specifically, event-related potentials 
[ERPs]) in patients with persistent pain after breast cancer 
surgery. To investigate possible changes in ERPs as a result 
of the presence of pain, these results (ie, from patients with 
pain) are compared with those in women without persistent 
pain after breast cancer surgery. In addition, we aim to 
investigate possible ERP changes as a result of breast cancer 
treatment by comparing the results of the patients without 
pain with healthy female volunteers. Our main hypothesis 
is that persistent pain is associated with an enhanced brain 
response to painful stimuli.
Materials and methods
Participants
Nineteen patients (eight women with pain and eleven without 
pain) who had been treated for breast cancer were recruited 
from a clinical database of the Radboud University  Nijmegen 
Medical Centre. Approval for the study was obtained 
from the Medical and Ethical Review Board Committee 
Region Arnhem-Nijmegen, Nijmegen, The Netherlands 
(NL 30189.091.09). All subjects signed an informed con-
sent form. At the moment of inclusion none had evidence 
of metastases or disease recurrences. All patients (with and 
without pain) had been operated more than 1 year ago at the 
time of participating. Patients had all undergone a mastec-
tomy or lumpectomy and ALND but no breast reconstruction. 
The rationale for investigating this population of patients is 
the high incidence of persistent pain after this type of surgery 
(mastectomy or lumpectomy + ALND).3,4 Only patients who 
had unilateral breast cancer were included. Persistent pain 
was defined as pain persisting continuously or intermittently 
for more than 3 months after surgery.17
Besides patients, eleven healthy female volunteers were 
also recruited from the Nijmegen area. Patients as well as 
healthy volunteers were excluded from the study if they:
1. had undergone breast reconstruction,
2. had a psychiatric or neurological condition (for patients, 
neurological signs as a result of the treatment were 
excepted),
3. used pain medication or other medication that poten-
tially affects brain processing, such as antidepressants, 
antipsychotics, antiepileptics, and benzodiazepines 
 (hormone therapy as adjuvant therapy used by the patients 
excepted),
4. suffered from any pre-existing pain or pain syndrome.
Subjects were instructed not to consume caffeine-
containing beverages for twelve hours before the recording 
session. This was to avoid a caffeine-induced theta decrease 
in EEG.18
Variables measured
Demographic and clinical characteristics
The composition of the two breast cancer surgery groups 
(with and without pain) was based on a standardized question 
(obtained via an interview by telephone) whether the patient 
experienced ongoing pain (yes or no) as a result of the breast 
cancer treatment. For confirmation, the same question was 
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asked again on the day of measurement, together with an 
additional standardized question (only if the patient expe-
rienced pain) regarding pain intensity as a measure of past 
experienced pain load (“What is the averaged intensity of the 
breast treatment-related pain during the last three months on 
a numeric 0–10 rating scale (NRS)?”).
Other demographic and clinical characteristics obtained 
were age, menopausal status, surgical treatment, and chemo-
therapy, radiation, and/or hormone therapy.
Patients who undergo ALND during breast cancer 
treatment are at risk for developing lymphedema.19 
Hypothetically, this could contribute to the persistence 
of pain. Therefore we measured limb volume differences 
(unaffected compared to affected limb) as an indirect 
reflection of the possible presence of lymphedema. To do 
so, we measured the limb volume of both sides (arms) via 
water displacement.20 Subjects were instructed to lower 
their arm slowly into a fully filled volume meter and asked 
to stop when the top of the volume meter came in contact 
with the axilla.20 The amount of spilt water was collected in 
a measuring cup (mL). The volume of the opposite (control) 
arm was also measured. The difference in volume of spilt 
water between the two sides (affected and control) was 
calculated. This test was also performed with the healthy 
volunteers to test if there are normally differences in volume 
between the two sides.
Data about the type of pain and pain-related sensory signs 
in the patients with pain were collected using the Douleur 
Neuropathique 4 (DN4) questionnaire.21,22 This question-
naire includes pain descriptors as well as three clinical tests 
reflecting altered somatosensory processing. The tests were 
performed by a physical therapist. For measuring hypoes-
thesia to touch, a brush (SENSElab, brush 05; Somedic, 
Horby, Sweden) was applied on different skin sites in the 
location of the pain. For measuring hypoesthesia to pinprick, 
a Semmes–Weinstein monofilament (nr. 5.07, 10.0 g) was 
applied to different skin areas in the location of the pain. For 
measuring brush evoked or increased pain within the location 
of pain, the same brush as for hypoesthesia was used. The 
effects of stimulation of the first two clinical tests (hypoes-
thesia to touch and pinprick) were quantified by comparing 
the skin sites in the location of pain to a control site on the 
contralateral body site.
It is important to mention that, in this study, the DN4 
questionnaire is not used as a screening or diagnostic 
instrument for neuropathic pain, because at present it is 
not validated for this purpose in this population of surgical 
patients. Thus we used the DN4 exclusively to collect data 
regarding the clinical qualitative characteristics of the pain 
syndrome.
Patients of both groups (with and without persistent 
pain) were asked if they had experienced tactile hypoes-
thesia or numbness since their treatment. If they did, they 
were asked to draw on a map the size and anatomical area 
of hypoesthesia.
Electrophysiological measures
A multichannel EEG (BrainVision; Brain Products GmbH, 
Waldkirch, Germany) was recorded during the experiment 
(band-pass 0.1–100 Hz, sample frequency 2000 Hz) with 
64 active electrodes mounted in an elastic electrode cap. 
The electrodes were arranged according to the international 
10–20 system and electrode CPz was used as common 
reference. Eye movements were detected by horizontal and 
vertical electrooculogram (EOG) recordings. Horizontal 
EOG was measured from the outer canthus of the left eye, 
and vertical EOG supra orbital to the left eye. Impedance 
was kept under 20 kΩ for all leads.
Painful stimulation
Subjects received painful stimulation on the calf, between 
the medial and lateral head of the gastrocnemius, using a 
concentric electrode (CE).23 Because of its concentric design 
and small anode–cathode distance, this stimulating electrode 
produces a high current density at relatively low current inten-
sities. In this way, depolarization is more limited to the super-
ficial layer of the dermis (where nociceptive [Aδ] fibers are 
present) with less recruitment of deeper lying nonnociceptive 
fibers. Stimulation with this electrode produces a pinprick-like 
painful sensation. The stimulated site was balanced across 
patients with regard to the affected side. In healthy subjects, 
balancing was according to lateral dominance.
The stimulation protocol consisted of 20 double pulses 
(monopolar square wave; duration 0.5 ms and double-pulse 
interval 5 ms) with a random interpair interval ranging from 
7 to 10 seconds. The double pulses were delivered through 
the CE using a constant current stimulator (Twister®; 
Dr Langer Medical GmbH, Waldkirch, Germany) and with 
an intensity of 150% of the individual pain threshold. This 
individual pain  threshold was determined by an ascend-
ing sequence of i ncreasing  current intensities starting from 
0 mA and in steps of 0.5 mA. This procedure stopped when 
the pain threshold was achieved, as verbally reported by 
the subjects. This threshold determination protocol was 
performed twice and the mean was used in the experiment 
to set intensity of stimulation.
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During stimulation, subjects were comfortably seated in 
a chair and were instructed to passively perceive the stimuli 
with eyes closed (as this condition is less prone to artifacts), 
without making any movements. A computer display was 
placed in front of the subject (0.5 m) together with a computer 
mouse. The display was used to show the visual analog scale 
(VAS) (see Behavioral measure), preceded by a tone (65 dB). 
Participants were instructed to open their eyes after the tone 
and use the mouse to mark the VAS, after which they closed 
their eyes again.
Behavioral measure
In order to quantify the amount of pain as a result of the 
painful stimulation, subjects were asked to rate, at random 
times within a train of five double pulses, the amount of pain 
caused by the last received stimulus on a VAS. The VAS 
ranged from 0 cm = ‘’no pain” to 10 cm = ‘’unbearable pain” 
and was rated by the subject by moving the mouse pointer 
(vertical line) on a horizontal bar.
Procedure
At the beginning of the experiment, demographic and clinical 
characteristics were collected. Next, the individual pinprick-
like pain thresholds for the double pulse stimulation were 
determined. Finally, subjects received the experimental pain-
ful stimulation with simultaneous recording of the EEG.
Signal analysis
Event-related potentials
The EEG was analyzed offline using Brain Vision Analyzer 
software (v. 2.0; Brain Products GmbH, Gliching, Germany) 
and MatLab (2011a; MathWorks, Natick, MA). As a first 
step, the continuous EEG was referenced to a common 
average (ie, all electrodes). Next, the EEG signal (2500 Hz) 
was high-pass filtered at 1 Hz and low-pass filtered at 30 Hz. 
Based on the onset of the stimulus, the EEG was segmented 
into epochs from −100 ms prestimulus to 1000 ms poststimu-
lus with a total period of 1100 ms. Bad segments containing 
ocular artifacts were corrected using the Gratton–Coles 
method.24 Segments were also inspected for other artifacts 
like muscle or jaw and line noise activity, and were removed 
if necessary. As a last step, baseline correction (−100–0 ms) 
was applied to all segments.
For each subject separately, all segments were averaged 
to obtain an averaged subject-specific event-related potential 
waveform. ERP components were defined in terms of their 
latency and topographic distribution. Subsequently the 
grand average global field power (GFP) of all subjects was 
calculated.25,26 Next, we calculated the topographic voltage 
distribution corresponding to the ERP latencies identified 
in the GFP plot. Then we identified the electrode in the 
topographic plot which showed the maximal activity, and 
used this electrode for subsequent analysis. To insure accurate 
identification of point of maximal activity we also inspected 
the grand average ERPs (of all electrodes) for all subjects.
Individual ERP latencies were determined in the 
individual GFP plot corresponding to the windows of the 
grand average GFP latencies.26 The mean amplitude of 
each ERP component was calculated at the individual GFP 
latency ± 5 ms at the electrode of maximal activity.26 The 
rationale for using the mean activity instead of the more 
commonly used maximal peak value (baseline-to-peak) is 
that, the fewer trials included in the subject-specific average, 
the more residual noise is superimposed on the maximal 
peak, and thus the more the maximal peak of the subject-
specific average will be determined by residual noise rather 
than by the peak of interest. Therefore, we calculated the 
mean amplitude instead of the maximal peak amplitude, 
because the former value is more stable and representative 
of evoked activity.27
Statistical analysis
The software package GraphPad Prism 5 (GraphPad, 
San Diego, CA) was used for statistical analysis. Because 
of the small sample sizes and non-Gaussian distributions, 
nonparametric test statistics were used for between-group 
comparisons. A Kruskall–Wallis test statistic (H) was used 
for ratio variables. In the present study only two pairs of post-
hoc comparisons were tested; healthy volunteers compared 
to patients without pain (effect of treatment) and patients 
without pain compared to patients with pain (effect of pain). 
The Dunn’s multiple comparisons test, which corrects for 
the number of statistical tests, was used as a post-hoc test. 
The effect size r was calculated as the Z-score divided by the 
square root of the total number of observations. Categorical 
variables were tested using the chi-squared (χ2) test statistic 
(P , 0.05).
Results
Clinical and demographical characteristics
Clinical and demographical characteristics are shown in 
Tables 1A–C and 2.
No statistically significant differences were observed 
between the three groups with respect to age and limb volume 
differences. Median age and limb volume differences scores 
(and interquartile ranges) are shown in Table 1A–C.
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Table 1 Demographic and clinical characteristics of the patients (A) with pain, (B) without pain and (C) healthy volunteers
(A)
Patient Age (years) Menopausal status Surgical treatment Additional treatment
Chemotherapy Radiation therapy Hormone therapy
1 52 Post Mast + ALND (II) Yes (FEC) Yes Yes (TAM)
2 50 Post Mast + ALND (II) Yes (TAC) Yes No
3 63 Post Mast + ALND (II) Yes (TAC) Yes Yes (TAM)
4 46 Post Mast + ALND (II) Yes (TAC) Yes Yes (TAM)
5 57 Post Mast + ALND (II) Yes (FEC) No Yes (TAM)
6 49 Post Lump + ALND (II) Yes (FEC) Yes Yes (TAM)
7 65 Post Mast + ALND (II) Yes (TAC) Yes Yes (TAM)
8 52 Post Mast + ALND (II) No No No
Median 52
Interquartile range 49–61
(%) 87.5 75.0 75.0
Patient Arm volume difference (mL) Location of pain Intensity pain (NRS)
Affected side – unaffected side Mean score of last 3 months
1 200 Arm + chest 6
2 −50 Arm 6
3 −60 Small area arm + chest (nipple and armpit) 6
4 20 Chest 3
5 170 Upper arm + chest 6
6 −40 Arm 3
7 60 Small area arm + chest 4
8 −110 Armpit (upper arm + top) + chest (scar) 4
Median −10 5
Interquartile range −57–142 3–6
(%)
(B)
Patient Age (years) Menopausal  
status
Surgical  
treatment
Additional treatment Arm volume  
difference (mL)
Chemo-
therapy
Radiation  
therapy
Hormone  
therapy
Affected side –  
unaffected side
1 32 Post Mast + ALND (II) Yes (TAC) No Yes (TAM) 30
2 49 Post Mast + ALND (III) Yes (TAC) Yes Yes (TAM) 260
3 58 Post Mast + ALND (II) Yes (FEC) No Yes (ARI) −50
4 45 Post Mast + ALND (II) Yes (TAC) Yes Yes (TAM) −80
5 42 Post Mast + ALND (II) Yes (FEC) No Yes (TAM) 0
6 53 Post Mast + ALND (II) Yes (TAC) Yes Yes (TAM) 170
7 58 Post Mast + ALND (II) Yes (TAC) No Yes (TAM) 100
8 56 Post Mast + ALND (III) Yes (TAC) Yes Yes (TAM) 330
9 47 Post Mast + ALND (III) Yes (TAC) Yes Yes (ARI) 140
10 65 Post Lump + ALND (II) No Yes Yes (ARI) 200
11 68 Post Lump + ALND (II) No Yes Yes (TAM) 
and (ARI)
100
Median 53 100
Interquartile range 45–58 0–200
(%) 81.8 63.6 100.0
(Continued)
A significant association (χ2 (2) = 7.972, P = .019) 
was observed between condition (healthy volunteers and 
patients) and menopausal status (pre- and post-). As can be 
seen in Table 1A–C, all patients (with and without pain) are 
postmenopausal, whereas 44% of healthy volunteers are 
premenopausal.
No significant associations were observed between 
the two patient groups (with and without pain) regarding 
the type of surgical intervention (mastectomy + ALND or 
lumpectomy + ALND) and incidences of adjuvant therapies 
(chemotherapy, radiation, or hormone therapy). See also 
Table 1A–C for incidences. The results obtained from the 
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DN4 questionnaire are shown in Table 2. Figure 1 shows the 
topography of hypoesthesia (numbness) drawn by the patients 
(with and without pain).
Stimulation intensity
No statistically significant differences were observed between 
the three groups regarding the applied stimulation intensities 
for noxious stimulation for ERPs. Median (and interquartile 
ranges) stimulation intensities were: healthy volunteers 
3.0 (2.7–4.2) mA, patients without pain 3.3 (3.0–3.7) mA, 
patients with pain 3.9 (2.7–4.7) mA.
Behavioral tests
No statistically significant differences were observed between 
the three groups regarding the VAS scores obtained during 
the noxious stimulation. Median VAS scores (and inter-
quartile ranges) were: healthy volunteers 4.2 (2.5–4.7) cm, 
patients without pain 3.0 (2.4–5.9) cm, patients with pain 
2.5 (1.6–4.2) cm.
Event-related potentials
Based on the grand average GFP and corresponding topo-
graphic representations of all subjects (N = 30) shown in 
Figure 2, we defined four distinctive ERP components:
1. A negative voltage between 110–180 ms, maximal at 
electrode FCz, which we label as N150,
2. A positive voltage between 190–230 ms, maximal at Cz, 
which we label as P200,
3. A positive voltage between 250–310 ms, maximal at FCz, 
which we label as P260,
4. A positive voltage between 310–380 ms, maximal at Cz, 
which we label as P350.
Figure 3 shows the topographic representations of the 
ERP components for each group at the ERP latencies.
Table 1 (Continued)
(C)
Control subject Age (years) Menopausal status Arm volume difference (mL)
Positive difference between left and right side
1 63 Post 60
2 40 Pre 20
3 50 Post 70
4 61 Post 30
5 46 Pre 10
6 41 Pre 20
7 42 Pre 80
8 56 Post 30
9 62 Post 40
10 60 Post 70
11 61 Post 190
Median 56 40
Interquartile range 42–61 20–70
Abbreviations: MAST, mastectomy; LUMP, lumpectomy; ALND, axillary lymph node dissection with between brackets the level of axillary dissection I, II, or III28; TAC, 
docetaxal (Taxotere®) + doxorubicin (Adriamycin®) + cyclophosphamide; FEC, fluorouracil + epurobicin + cyclophosphamide; ARI, Arimidex®; TAM, tamoxifen.
Table 2 Results of the Douleur Neuropathique 4 questionnaire
Pain charcteristics Symptoms associated with the pain Symptoms present in pain location
Burning Painful  
cold
Electrical  
shocks
Tingling Pins and  
needles
Numbness Itching Hypoesthesia  
to touch
Hypoesthesia  
to pinprick
Pain after 
brushing
1 – – X X – X – – X –
2 X – – – – X – X X –
3 – – X X X X – X X –
4 – – – – – X X X X –
5 – – X – X X – X X –
6 – X X X X X – – – X
7 X – – – X X – X X –
8 X – X – X X – – X –
% patients 37.5% 12.5% 62.5% 37.5% 62.5% 100.0% 12.5% 62.5% 87.5% 12.5%
Notes: Shown are the individual patient characteristics as well as group percentages regarding type of pain, associated symptoms and clinical tests of the patients with 
persistent pain. – = no, X = yes.
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ERP amplitude
There were no statistically significant differences regard-
ing N150, P200, and P350 between groups. Median and 
interquartile ranges are shown in Table 3. A statistical dif-
ference was observed for the P260 between the three groups 
(H (2) = 6.490, P = 0.039). Dunn’s post-hoc tests revealed a sta-
tistically significant difference between patients with pain com-
pared to patients without pain (P , 0.05; effect size r = −0.49). 
Grand average ERPs of P260 are shown in Figure 4.
ERP latency
A statistically significant difference was observed between 
the three groups (H (2) = 9.367, P = 0.009) regarding 
P260 latency. Dunn’s post-hoc tests revealed a statistically 
significant difference between patients without pain and 
healthy volunteers (P , 0.05; effect size r = 0.58) but also 
between patients with pain compared to patients without pain 
(P , 0.05; effect size r = −0.56). Median and interquartile 
ranges are shown in Table 3.
Patients without pain
Patients with pain 75.0%
62.5%
50.0%
37.5%
25.0%
12.5%
54.5%
45.5%
36.4%
27.3%
18.2%
9.1%
Figure 1 Area of tactile hypoesthesia (numbness). 
Notes: This figure shows the topographical map of areas of tactile hypoesthesia (numbness) drawn by the patients without pain and with pain. The scale of percentages 
shown in the legend represents the number of patients (converted to percentages) who marked that area as hypoesthetic.
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Discussion
To our knowledge, this is the first study to investigate cortical 
processing by means of EEG and with this kind of stimuli 
in this group of patients. In comparison to patients without 
persistent pain, persistent pain after breast cancer treatment is 
associated with delayed and enhanced stimulus processing as 
reflected in an increased latency and enhanced amplitude of 
the ERP positivity between 250–310 ms (P260).  Moreover, 
in comparison to healthy volunteers, breast cancer treatment 
is associated with acceleration of (reduced P260 latency) and 
a tendency towards less intense (smaller P260 amplitude) 
stimulus processing. These results suggest that the two 
conditions, ie, treatment and pain persistence, have opposite 
effects regarding cortical responsiveness.
Breast cancer treatment  
and cortical processing
The comparison between the patients without pain and the 
healthy volunteers reveals the effect of treatment on corti-
cal processing. This comparison revealed an acceleration of 
stimulus processing (reduced P260 latency) in the patients 
without pain compared to the healthy volunteers. Moreover, 
there is a smaller late ERP amplitude (P260) in the patients 
without pain compared with the healthy volunteers, although 
this is not statistically significant according to the Dunn’s 
post hoc test. This is probably due to the small sample sizes 
and the fact the P value has to be corrected for multiple 
comparisons. Indeed, the effect size is r = −0.45.
Kreukels et al29 also observed a lower ERP amplitude 
in  disease-free breast cancer survivors who were treated for 
breast cancer (including surgery and radiotherapy). All patients 
underwent surgery and radiotherapy. In this study, the authors 
investigated the effect of different chemotherapy regimens on 
ERP activity in response to auditory stimuli (by using an odd-
ball paradigm). Overall, they observed significantly reduced 
late ERP (ie, P3) amplitude between patients that received 
chemotherapy as compared to matched control patients who 
had not received chemotherapy. Moreover, a shorter P3 latency 
was observed after chemotherapy. The authors did not find any 
changes in midlatency N1 ERP amplitude or latency between 
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Figure 2 Grand average global field power (GFP) and corresponding topographic representations. (A) Grand average GFP (N = 30). The dotted lines indicate peak latency 
of the different event-related potential (ERP) components. Four different components can be identified: a negative voltage between 110–180 ms, maximal at FCz, labeled 
as N150, a positive voltage between 190–230 ms, maximal at Cz, labeled as P200, a positive voltage between 250–310 ms, maximal at FCz, labeled as P260, and a positive 
voltage between 310–380 ms, maximal at Cz and labeled as P350. (B) Topographic representations of the ERP components at the ERP latencies (N = 30). To best illustrate 
the maximal activity in each representation, we adjusted the scale to its maximal absolute values (for increases and decreases in voltages). As a result the scale differs between 
the different representations and is therefore left out.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
146
van den Broeke et al
Journal of Pain Research 2012:5
the two groups (with and without chemotherapy), a finding 
in agreement with the present study.
Are there alternative factors that can explain the reduced 
brain activity? Regarding hormone therapy, Kreukels et al29 
performed an additional subanalysis on their data in which they 
compared the ERP P3 amplitude between current, past, and 
never users of tamoxifen. They found no significant  difference 
in P3 amplitude between the three groups,  suggesting that 
tamoxifen (and perhaps also other hormone therapy regi-
mens) cannot explain the observed ERP reduction.
An as yet undefined pathophysiological process subse-
quent to amputation, eg, deafferentation, might also change 
EEG activity.30 This argument is based on the study by 
Karl et al.30 Although not statistically significantly different, 
a lower P3 amplitude was observed in the amputees without 
pain compared to the healthy controls.
Healthy
volunteers
N150 (154.8 ms) P200 (208.0 ms) P260 (262.0 ms) P350 (344.4 ms)
Patients
without pain
Patients
with pain
Decrease
(µV/m2)
Increase
(µV/m2)
Figure 3 Group-specific topographic representations. Shown are the topographic representations of the different event-related potential (ERP) components at the different 
ERP latencies (Figure 2).
Notes: To best illustrate the maximal activity in each representation, we adjusted the scale to its maximal absolute values (for increases and decreases in voltages). As a 
result the scale differs between the different representations and is therefore left out.
Table 3 Event-related potential (ERP) amplitude and latencies
Healthy volunteers Patients without pain Patients with pain
Amplitude 
(μV)
Latency 
(ms)
Amplitude 
(μV)
Latency 
(ms)
Amplitude 
(μV)
Latency 
(ms)
N150 (FCz) −2.2 
(−7.0–2.4)
133.2 
(128.0–159.6)
−4.6 
(−6.7–1.1)
148.8 
(123.2–176.4)
−3.4 
(−8.1–0.8)
156.2 
(146.8–161.8)
P200 (Cz) 2.7 
(−1.9–4.1)
196.8 
(190.0–218.4)
−1.5 
(−5.0–1.5)
208.0 
(196.4–224.4)
0.5 
(−0.9–4.9)
203.4 
(198.2–227.7)
P260 (FCz) 4.0 
(2.9–6.8)
279.2 
(266.8–302.8)
1.3 
(−0.6–4.1)
255.6 
(250.0–266.0)
5.7 
(2.5–8.2)
284.4 
(265–305.2)
P350 (Cz) 3.6 
(2.5–7.3)
355.6 
(320.8–380.0)
3.0 
(0.6–5.1)
348.4 
(332.0–372.4)
4.3 
(3.0–8.9)
336.8 
(327–351.5)
Note: Shown are the medians (and interquartile ranges) of the ERP amplitudes and latencies of the different groups.
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When we look at the clinical and demographic charac-
teristics (Table 1), the proportion of premenopausal status 
among the healthy women compared to the patients without 
pain is different. Theoretically, this could be a further factor 
explaining the differences in P260 amplitude between the 
two groups.
Persistent pain and cortical processing
The comparison between the patients with and without pain 
reveals the effect of the presence of persistent postsurgical 
pain on cortical processing. Based on the results mentioned in 
the previous section, we suggest that breast cancer treatment 
(ie, chemotherapy) affects late ERP activity, ie, lower ERP 
amplitude and shorter latency. The larger ERP amplitude (and 
increased latency) seen in the patients with pain compared to 
the patients without pain is likely the result of the presence 
of pain additional to the effect of breast cancer treatment. 
Therefore, we conclude that persistent pain after breast cancer 
treatment is associated with delayed (increased P260 latency) 
and enhanced (larger P260 amplitude) stimulus processing.
Interestingly, Karl et al,30 using an oddball paradigm, 
compared visual P3 amplitude between upper limb amputees 
with and without persistent pain and healthy volunteers. 
Patients with pain showed significantly higher P3 amplitudes 
than patients without pain, but neither group were statistically 
different from the healthy volunteers. The latter result could 
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Figure 4 Event-related potential (ERP) waveforms. Grand average ERPs observed from FCz showing the P260 differences (A) effect of treatment, (B) effect of pain.
Notes: Upward deflection is positive charge and downward is negative charge. Representations of ERPs are with respect to common reference.
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be due to the small sample sizes (patients with pain, N = 5; 
patients without pain, N = 5; and healthy volunteers, N = 10). 
However, the ERP findings observed in the study of Karl et al 
appear to involve later ERP activity (between 300–500 ms) 
than in our study (between 250–310 ms). Possible explana-
tions for the different ERP activities affected in the two 
studies are the type of stimulus and paradigm used.
Methodological considerations
Defining (late) ERP components
The positivity around 260 ms (ie, P260) shares the same 
time course and topographic distribution as the previously 
described SP5 component (233–277 ms) evoked after painful 
electrical stimulation.31 This ERP component seems to over-
lap with the greater later positivity SP6 or pain-related P2.
The positivity around 350 ms, labeled as P350, might 
be the pain-related P2 evoked after painful electrical 
stimulation.31,32 By comparing laser stimulation with electri-
cal sural nerve stimulation, Dowman showed that this P2, 
evoked after painful stimulation, has similar properties to the 
commonly described P2, associated with selective Aδ fiber 
activation, evoked after painful laser stimulation.33–36
However, Mouraux et al35 recently compared electrical 
intraepidermal, electrical nonnociceptive transcutaneous and 
laser stimulation for their selectivity in generating Aδ fiber-
associated evoked brain responses. They showed that only 
laser and low intensity electrical intraepidermal stimulation 
are able to evoke Aδ-associated evoked brain responses. 
Additionally, they showed that intraepidermal stimula-
tion loses its selectivity with increasing stimulus intensity, 
something that occurred above intensities of 2.5 mA.35 
In the present study we used transcutaneous electrical stimu-
lation with stimulation intensities around 3.0 mA, which 
indicates against the possibility that we selectively evoked 
Aδ-associated brain responses.
Alternatively, the P350 could be a P3a-like component.31,37,38 
This hypothesis can be supported by the facts that:
1. A “single stimulus” paradigm as used in the present study, 
in which only target but no standard stimuli are delivered 
with long, variable and random interstimulus intervals, is 
able to evoke a P3a-like component,39,40 also after painful 
electrical stimulation,31 and
2. this positivity shares the same generators in the brain 
as the classic P3a, as is demonstrated via intracranially-
recorded cortical responses evoked after painful electrical 
stimulation. These generators include the dorsolateral and 
medial prefrontal cortices, temporal-parietal junction and 
posterior hippocampus.37
Area of stimulation
In the present study, the painful stimuli were applied to a body 
part somatopically remote from the initially injured or painful 
area. We choose to do this because we wished to investigate 
cortical changes in pain processing (which one would expect to 
be generalized). For this, we need to stimulate in an area remote 
from the spinal segment undergoing nociceptive input due to 
breast cancer treatment. Our study therefore reflects only gener-
alized but not localized effects of surgery or radiation therapy.
Sample size
An important methodological limitation of this study is the 
small sample size. This was the result of our opting for more 
strict inclusion and exclusion criteria (to avoid confound-
ing factors), but has the advantage that the resulting patient 
groups are very homogenous. Nevertheless, the ERP effects 
observed in the present study should be confirmed in a new 
future study with larger sample sizes.
Conclusions
This observational study shows that the two conditions, ie, 
treatment and persistent pain, have opposite effects regarding 
cortical responsiveness. Breast cancer treatment is associated 
with an acceleration of and a tendency to less intense stimulus 
processing. Persistent pain after breast cancer treatment is 
associated with delayed and enhanced stimulus processing. 
To our knowledge, this is the first study to investigate cortical 
processing by means of EEG and with this kind of stimuli in 
this group of patients.
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